Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shawn Sanicola

Podiatrist Pewaukee, WI Doctor of Podiatric Medicine

NPI 1457356305 CMS profile 111548

2835 N Grandview Blvd Ste 300, Pewaukee, WI 53072

Open in the dashboard

General payments

$3,021

74 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shawn Sanicola of Pewaukee, WI is reported in the CMS Open Payments database as having received $3,021 across 74 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $442 15
2024 General $523 13
2023 General $308 9
2022 General $394 14
2021 General $135 6
2019 General $1,220 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shawn Sanicola
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Shawn Sanicola were reported at $442. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Shawn Sanicola Podiatrist median Middle half National median
2019 $1,220 $196 $72–$601 $163
2020 $0 $118 $38–$335 $114
2021 $135 $169 $57–$573 $132
2022 $394 $220 $74–$782 $149
2023 $308 $208 $71–$635 $160
2024 $523 $237 $87–$681 $164
2025 $442 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $1,166 14 payments
  2. Smith+Nephew, Inc. $314 12 payments
  3. Stryker Corporation $265 6 payments
  4. DePuy Synthes Sales Inc. $228 5 payments
  5. Kerecis Limited $189 3 payments
  6. Fusion Orthopedics USA, LLC $160 5 payments
  7. Aroa Biosurgery Incorporated $87 2 payments
  8. Integra LifeSciences Corporation $77 2 payments
  9. Bioventus LLC $60 2 payments
  10. Djo, LLC $48 2 payments
  11. Other $427 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,056 66 payments
  2. Travel and Lodging $815 6 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $134 1 payment
  4. Entertainment $17 1 payment
Products named General payments · program years 2019–2025
  1. Puraply, NuShield, Affinity $967 9 payments
  2. Bone Anchors with Arthroscopic Delivery System $138 3 payments
  3. Kerecis Omega3 SurgiClose $137 2 payments
  4. Kerecis Omega3 Marigen $137 2 payments
  5. Apligraf $134 1 payment
  6. Dermagraft $134 1 payment
  7. Puraply/Affinity/NuTech $134 1 payment
  8. DYNATAPE $114 2 payments
  9. CARTIVA SYNTHETIC CARTILAGE IMPLANT $101 2 payments
  10. AUGMENT INJECTABLE $94 2 payments
  11. Other $2,500 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

64

Median for Podiatry: 160

Drug cost

$442

Median for Podiatry: $2,368

Branded share of claims

70.3%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 19 $169
Methylprednisolone Generic 19 $159
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $62
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 11 $52

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$75,266

Of which drugs: $97

Medicare patients

391

Average age 77

Services billed

1,580

221 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 38%
Chronic kidney disease 34%
Ischemic heart disease 31%
Atrial fibrillation 24%
Heart failure 20%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 47 134 $96

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

74 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record